Deutsche Bank
MLYS icon

Deutsche Bank’s Mineralys Therapeutics MLYS Stock Holding History

Deutsche Bank’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.09M Buy
40,116
+2,871
+8% +$84.2K ﹤0.01% 2134
2025
Q4 		$1.35M Buy
37,245
+6,315
+20% +$253K ﹤0.01% 2031
2025
Q3 		$1.17M Sell
30,930
-425,984
-93% -$9.21M ﹤0.01% 2074
2025
Q2 		$6.18M Buy
456,914
+160,899
+54% +$2.33M ﹤0.01% 1157
2025
Q1 		$4.7M Buy
296,015
+269,283
+1,007% +$3.1M ﹤0.01% 1276
2024
Q4 		$329K Buy
26,732
+10,264
+62% +$134K ﹤0.01% 2851
2024
Q3 		$199K Buy
16,468
+4,836
+42% +$58.5K ﹤0.01% 2926
2024
Q2 		$136K Buy
11,632
+3,299
+40% +$41.5K ﹤0.01% 3009
2024
Q1 		$108K Buy
+8,333
New +$103K ﹤0.01% 3136
2023
Q4 		– Sell
-5,678
Closed -$54K – 3675
2023
Q3 		$54K Hold
5,678
– – ﹤0.01% 3394
2023
Q2 		$96.8K Sell
5,678
-1,827
-24% -$27.3K ﹤0.01% 3288
2023
Q1 		$118K Buy
+7,505
New +$126K ﹤0.01% 3255

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Deutsche Bank's MLYS Position: Q1 2026 in Review

Deutsche Bank increased its Mineralys Therapeutics (MLYS) stake by 7.7% in Q1 2026, buying an estimated $84.2K and bringing the position to 40,116 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2134.

Deutsche Bank first reported a position in MLYS in Q1 2023 and has held it in 12 quarters since. The position peaked at $6.18M in Q2 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Deutsche Bank held 40,116 shares of Mineralys Therapeutics worth $1.09M as of Q1 2026.
  • Deutsche Bank bought 2,871 Mineralys Therapeutics shares in Q1 2026, an estimated $84.2K.
  • Mineralys Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #2134 holding.
  • Deutsche Bank first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • Deutsche Bank's Mineralys Therapeutics position peaked at $6.18M in Q2 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.